Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
2022 · Journal of the National Comprehensive Cancer Network · 1,599 citations
https://doi.org/10.6004/jnccn.2022.0008
P
Peter C. Enzinger
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
274
Papers
24.8K
Citations
62
h-index
126
i10-index
Peter C. Enzinger is an academic researcher from Dana-Farber Cancer Institute. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Esophageal Cancer Research and Treatment & Colorectal Cancer Treatments and Studies. The author has an h-index of 62, co-authored 233 publications.
Papers by this author
worksPembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
2021 · The Lancet · 1,479 citations
https://doi.org/10.1016/s0140-6736(21)01234-4
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
2020 · Journal of Clinical Oncology · 1,151 citations
https://doi.org/10.1200/jco.20.01888
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 · The Lancet · 609 citations
https://doi.org/10.1016/s0140-6736(23)00620-7
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
2023 · Journal of the National Comprehensive Cancer Network · 450 citations
https://doi.org/10.6004/jnccn.2023.0019
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
2023 · Nature Medicine · 450 citations
https://doi.org/10.1038/s41591-023-02465-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat